The study included 15 men, eight patients with metastatic hormone sensitive PCa treated with luteinizing hormone-releasing hormone and bicalutamide and seven patients with castration resistant PCa treated with enzalutamide or abiraterone, and showed that at 9 days post treatment, [68Ga]Ga-PSMA-11 PET/CT SUVmax decreased in the hormone-sensitive patients (median 30% (interquartile range 5–61) but increased in the castration-resistant PCa (median 45% (interquartile range 12.7–66)). Here, FOLH1 is linked to posterior cortical atrophy.